List of Vantrela Er drug patents

Vantrela Er is owned by Teva Branded Pharm.

Vantrela Er contains Hydrocodone Bitartrate.

Vantrela Er has a total of 3 drug patents out of which 0 drug patents have expired.

Vantrela Er was authorised for market use on 17 January, 2017.

Vantrela Er is available in tablet, extended release;oral dosage forms.

The generics of Vantrela Er are possible to be released after 31 July, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572803 TEVA BRANDED PHARM Abuse resistant drug formulation
Sep, 2027

(4 years from now)

US9216176 TEVA BRANDED PHARM Abuse resistant drug formulation
Sep, 2027

(4 years from now)

US8445018 TEVA BRANDED PHARM Abuse resistant drug formulation
Jul, 2029

(6 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 17 January, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in